Initial Antituberculous Regimen with Better Drug Penetration into Cerebrospinal Fluid Reduces Mortality in HIV Infected Patients with Tuberculous Meningitis: Data from an HIV Observational Cohort Study

Table 2

Crude and multivariable Cox regression analyses of factors associated with mortality in HIV patients with tuberculous meningitis.

	Crude analysis		Complete case MA		Multiple imputation MA
			𝑁=176		𝑁=203
	HR	95% CI	aHR	95% CI	aHR	95% CI
iATR
New	1		1		1
Standard	1.82*	(1.095–3.020)	1.88*	(1.081–3.261)	2.05*	(1.209–3.462)
Age (years)
<35	1.06	(0.711–1.573)	1.16	(0.695–1.922)	1.09	(0.692–1.729)
>35	1		1		1
Gender
Female	1.05	(0.683–1.601)	0.93	(0.538–1.594)	0.85	(0.514–1.405)
Male	1		1		1
Disadvantaged community
No	1		1		1
Yes	1.59*	(1.052–2.399)	1.19	(0.717–1.963)	1.27	(0.811–1.974)
Homeless
No	1		1		1
Yes	0.89	(0.361–2.201)	1.05	(0.382–2.874)	1.02	(0.378–2.766)
Illiterate
No	1		1		1
Yes	1.31	(0.877–1.954)	1.12	(0.662–1.889)	1.18	(0.736–1.881)
Depressed consciousness
No	1		1		1
Yes	1.36	(0.913–2.021)	1.21	(0.751–1.939)	1.30	(0.852–1.987)
Previous tuberculosis
No	1		1		1
Yes	1.09	(0.657–1.792)	1.54	(0.795–2.966)	1.50	(0.845–2.678)
Months on ART
>6 months	0.63	(0.367–1.098)	0.82	(0.403–1.678)	0.76	(0.399–1.439)
<6 months	0.50*	(0.291–0.852)	0.59	(0.310–1.142)	0.56*	(0.311–0.995)
No ART	1		1		1
CD4 count (cells/𝜇L)
≤50	3.04*	(1.885–4.901)	1.93*	(1.086–3.427)	1.95*	(1.132–3.372)
51–100	1.34	(0.766–2.346)	1.24	(0.665–2.322)	1.27	(0.707–2.279)
>100	1		1		1
Sodium (mEq/L)
≤135	1		1		1
>135	0.58*	(0.358–0.956)	0.66	(0.379–1.133)	0.70	(0.410–1.181)
Albumin (g/dL)
≤2.5	3.95*	(2.163–7.231)	3.66*	(1.490–9.008)	3.14*	(1.433–6.898)
2.6–3.8	1.92*	(1.139–3.227)	1.95*	(1.029–3.691)	1.92*	(1.093–3.380)
>3.8	1		1		1
Haemoglobin (g/dL)
≤9	1.48	(0.973–2.239)	0.78	(0.421–1.428)	0.76	(0.434–1.330)
>9	1		1		1

^∗𝑃 value < 0.05; aHR, adjusted hazard ratio; ART: antiretroviral therapy; iATR: initial antituberculous regimen; HR: hazard ratio; MA: multivariable analysis.